Evidence map›Paper›PMID 27664710›Full record

ArticleThe Journal of investigative dermatology2016

NRAS, NRAS, Which Mutation Is Fairest of Them All?

Christine Grill, Lionel Larue

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Relative genotoxicity of polycyclic aromatic hydrocarbons inferred from free energy perturbation approaches.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Christine GrillInstitut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U1021, Normal and Pathological Development of Melanocytes, Orsay, France; Université Paris-Sud, Université Paris-Saclay, Centre National de la Recherche Scientifique Unité Mixte de Recherche 3347, Orsay, France; Equipe Labellisée Ligue Contre le Cancer, Orsay, France.
Lionel LarueInstitut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U1021, Normal and Pathological Development of Melanocytes, Orsay, France; Université Paris-Sud, Université Paris-Saclay, Centre National de la Recherche Scientifique Unité Mixte de Recherche 3347, Orsay, France; Equipe Labellisée Ligue Contre le Cancer, Orsay, France. Electronic address: lionel.larue@curie.fr.
Institut Curie · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 28% of melanomas, NRAS is mutated in one of two hotspots: G12 or Q61. Phosphoproteomic analysis of primary human melanocytes transduced with G12 and Q61 showed different phosphorylation events in the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Surprisingly, NRAS(G12) modulates the PI3K pathway and overexpresses the kinase PIM2, whereas NRAS(Q61) is associated with the MAPK pathway and overexpression of CK2α.

Indexed as

HumansMelanocytesMelanomaMitogen-Activated Protein KinasesMutationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafMitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins B-raf

Identifiers

PMID27664710
OpenAlexW2522369558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.